Valuation Spero Therapeutics, Inc. Börse Stuttgart
Stocks
2HA
US84833T1034
Biotechnology & Medical Research
|
Market Closed -
Börse Stuttgart
22:55:33 09/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.001 EUR | -1.86% |
|
-0.78% | -46.48% |
| 08-13 | Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Spero Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 517.5 | 89.57 | 77.91 | 56.15 | 131.3 | 68.13 | - |
| Change | - | -82.69% | -13.02% | -27.92% | 133.77% | -48.1% | - |
| Enterprise Value (EV) | 371.1 | 89.57 | 77.91 | 56.15 | 131.3 | 68.13 | 68.13 |
| Change | - | -75.86% | -13.02% | -27.92% | 133.77% | -48.1% | 0% |
| P/E | -5.5x | -1.41x | 3.42x | -0.81x | 15.5x | -4.03x | 1.75x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0x | -0x | 0x | -0x |
| Capitalization / Revenue | 28,346,906x | 1,673,972x | 750,706x | 1,170,430x | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -2.91 | -1.23 | 0.43 | -1.27 | 0.15 | -0.29 | 0.67 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales | 18.26 | 53.51 | 103.8 | 47.98 | - | - | - |
| EBITDA | -87.32 | - | - | - | - | - | - |
| EBIT | -87.97 | -42.2 | 21.48 | -73.36 | - | - | - |
| Net income | -89.76 | -46.42 | 22.81 | -68.57 | - | - | - |
| Net Debt | -146.4 | - | - | - | - | - | - |
| Reference price 2 | 16.010 | 1.730 | 1.470 | 1.030 | 2.330 | 1.170 | 1.170 |
| Nbr of stocks (in thousands) | 32,324 | 51,776 | 52,999 | 54,518 | 56,339 | 58,235 | - |
| Announcement Date | 3/31/22 A | 3/30/23 A | 3/13/24 A | 3/27/25 A | 3/26/26 A | - | - |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.31x | 7.19x | 14.43x | 1.46% | 69.19B | |
| 35.78x | 9.33x | 28.47x | 0.04% | 62.97B | |
| -76.45x | 14.75x | -71.13x | -.--% | 27.27B | |
| -14.89x | 5.5x | -6.92x | -.--% | 24.78B | |
| 29.76x | 6.36x | 16.51x | -.--% | 25.8B | |
| 27.41x | 5.13x | 17.28x | -.--% | 20.11B | |
| 52.99x | 19.62x | 39.8x | 0.28% | 18.47B | |
| 1285.53x | 37.11x | 809.82x | -.--% | 14.88B | |
| 17.81x | 5.31x | 12.39x | -.--% | 14.29B | |
| Average | 153.14x | 12.26x | 95.63x | 0.2% | 30.86B | |
| Weighted average by Cap. | 82.37x | 10.37x | 51.89x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRO Stock
- 2HA Stock
- Valuation Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
